Legal and ethical issues involving marine biodiscovery and development

Handbook of Marine Natural Products

Volumn , Issue , 2012, Pages 1315-1342

  Cragg, Gordon M ^a   Katz, Flora ^b   Newman, David J ^a   Rosenthal, Joshua ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84876916784     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-90-481-3834-0_27     Document Type: Chapter

References (42)

1. Newman DJ, Cragg GM (2007) Natural products as sources of new drugs over the last 25 years. J Nat Prod 70: 461-477
2. Newman DJ, Cragg GM (2004) Marine natural products and related compounds in clinical and advanced preclinical trials. J Nat Prod 67: 1216-1238
3. Newman DJ, Cragg GM (2009) Recent progress of natural marine products as anticancer drugs. In: Chabner B (ed) Marine anticancer compounds in the era of targeted therapies. P Permanyer SL, Barcelona
4. Eisner T, Meinwald J (1990) The Goteborg resolution. Chem Ecol 1:38
5. Baker JT, Borris RP, Carte B, Cordell GA, Soejarto DD, Cragg GM, Gupta MP, Iwu MM, Madulid DR, Tyler VE (1995) Natural product drug discovery and development: new perspectives on international collaboration. J Nat Prod 58: 1325-1357
6. Cragg GM, Baker JT, Borris RP, Carte B, Cordell GA, Soejarto DD, Gupta MP, Iwu MM, Madulid DR, Tyler VE (1997) Interactions with source countries. Guidelines for members of the American society of pharmacognosy. J Nat Prod 60: 650-655
7. Fischli AE, Pandit UK, St C, Black D (2002) Molecular basis of biodiversity, conservation, and sustained innovative utilization (IUPAC technical report). Pure Appl Chem 74: 697-702
8. Reid WV, Laird SA, Meyer CA, Gamez R, Sittenfeld A, Janzen DH, Gollin MA, Juma C (1993) Biodiversity prospecting. World Resources Institute, Baltimore
9. Grifo F, Rosenthal J (eds) (1997) Biodiversity and human health. Island Press, Washington, DC
10. ten Kate K, Laird SA (1999) The commercial use of biodiversity. Earthscan, London
11. Svarstad H, Dhillon SS (2000) Responding to bioprospecting. Spartacus Forlag AS, Oslo
12. Sampath PG (2005) Regulating bioprospecting. United Nations University Press, Tokyo/New York/Paris
13. Cragg GM, Grothaus PG, Newman DJ (2009) Impact of natural products on developing new anti-cancer agents. Chem Rev 109: 3012-3043
14. Newman DJ, Cragg GM (2005) The discovery of anticancer drugs from natural sources. In:Zhang L, Fleming GA, Demain AL (eds) Natural products: drug discovery, therapeutics, and preventative medicine. Dekker, New York, pp 129-168
15. Mays TD, Mazan KD, Cragg GM, Boyd MR (1997) Triangular privity-a working paradigm for the equitable sharing of benefits from biodiversity research and development. In: Hoagland KE, Rossman AY (eds) Global genetic resources: access, ownership and intellectual property rights. Association of Systematics Collections, Washington, DC, pp 279-298
16. Kaufman D (1993) Botany 2000. ASIA Newsl 2:6
17. Kashman Y, Gustafson KR, Fuller RW, Cardellina JH II, McMahon JB, Cragg GM, Boyd MR (1992) The calanolides, a novel HIV-inhibitory class of coumarins derivatives from the tropical rainforest tree, Calophyllum lanigerum. J Med Chem 35: 2735-2743
18. ten Kate K, Wells A (1998) Benefit-sharing case study: access and benefit-sharing policies of the United States National Cancer Institute: a comparative account of the discovery and development of the drugs Calanolide and Topotecan. Executive Secretary of the Convention on Biological Diversity. http://www.cbd.int/doc/case-studies/abs/cs-abs-nci.pdf. Accessed 2 Nov 2011
19. Rosenthal JP, Katz F (2003) Natural products research partnerships with multiple objectives in global biodiversity hotspots: nine years of the ICBG program. In: Bull A (ed) Microbial diversity and bioprospecting. ASM Press, Washington, DC
20. Rosenthal JP (1997) Equitable sharing of biodiversity benefits: agreements on genetic resources. In: Investing in biological diversity-proceedings of the international conference on biodiversity incentive measures. OECD Press, Paris
21. Rosenthal JP, Beck D, Bhat A, Biswas J, Brady L, Bridbord K, Collins S, Cragg G, Edwards J, Fairfield A, Gottlieb M, Gschwind L, Hallock Y, Hawks R, Hegyeli R, Johnson G, Keusch G, Lyons E, Miller R, Rodman J, Roskoski J, Siegel-Causey D (2000) Combining high-risk science with ambitious social and economic goals. Pharm Biol 37(Suppl): 6-21
22. Soejarto DD, Gyllenhaal C, Fong HHS, Xuan LT, Hiep NT, Hung NV, Bich TQ, Southavong B, Sydara K, Pezzuto JM (2004) The UIC ICBG (University of Illinois at Chicago International Cooperative Biodiversity Group) memorandum of agreement: a model of benefit-sharing arrangement in natural products drug discovery and development. J Nat Prod 67: 294-299
23. Rosenthal JP (2007) Politics, culture and governance in the development of prior informed consent and negotiated agreements with indigenous communities. In: McManis C (ed) Biodiversity, biotechnology and traditional knowledge. Earthscan, London
24. Eisenman E, Zaurov D, Struwe L (eds) (2010) Medicinal plants of central Asia: Kyrgyzstan and Uzbekistan. The New York Botanical Garden Press, New York (in press)
25. Gutiérrez M, Tidgewell K, Capson TL, Engene N, Almanza A, Schemies J, Jung M, Gerwick WH (2010) Malyngolide dimer, a bioactive symmetric cyclodepside from the Panamanian marine cyanobacterium Lyngbya majuscula. J Nat Prod 73(4): 709-711
26. Medina RA, Goeger DE, Hills P, Mooberry SL, Huang N, Romero LI, Ortega-Barria E, Gerwick WH, McPhail KL (2008) Coibamide A, a potent antiproliferative cyclic depsipeptide from the Panamanian marine cyanobacterium Leptolyngbya sp. J Am Chem Soc 130: 6324-6325
27. Capson TL (2006) Panama’s Coiba National Park: a jewel of the tropical eastern Pacific. World Herit 42: 24-29
28. Kursar TA, Caballero-George CG, Capson TL, Cubilla-Rios L, Gerwick WH, Gupta MP, Ibanez A, Linington RG, McPhail KL, Ortega-Barria E, Romero LI, Solis PN, Coley PD (2006) Securing economic benefits and promoting conservation through bioprospecting. Bioscience 56: 1005-1012
29. Kursar TA, Caballero-George CC, Capson TL, Cubilla-Rios L, Gerwick WH, Heller MV, Ibanez A, Linington RG, McPhail KL, Ortega-Barria E, Romero LI, Coley PD (2007) Linking bioprospecting with sustainable development and conservation: the Panama case. Biodivers Conserv 16: 2789-2800
30. Williams C, Espinosa OA, Montenegro H, Cubilla L, Capson TL, Ortega-Barria E, Romero L (2003) Hydrosoluble formazan XTT: its application to natural products drug discovery for Leishmania. J Microbiol Meth 55: 813-8161
31. Corbett Y, Herrera L, Gonzalez J, Cubilla-Rios L, Capson TL, Coley PD, Kursar TA, Romero LI, Ortega-Barria E (2004) A novel DNA-based microfluorimetric method to evaluate antimalarial drug activity. Am J Trop Med Hyg 70: 119-124
32. Aalbersberg B, Tawake A, Parras T (2005) Village by village: recovering Fiji’s coastal fisheries. In: The wealth of the poor: managing ecosystems to fight poverty. World Resources Institute, Washington, DC, pp 144-151
33. Sanders JM (2005) Reefing the benefits. Res Horiz 23: 6-11
34. Kubanek J, Prusak AC, Snell TW, Giese RA, Hardcastle KI, Fairchild CR, Aalbersberg W, Raventos-suarez C, Hay ME (2005) Anti-neoplastic diterpene-benzoate macrolides from the Fijian red alga Callophycus serratus. Org Lett 7(5261):5264
35. Kubanek J, Prusak AC, Snell TW, Giese RA, Fairchild CR, Aalbersberg W, Hay ME (2006) Bromophycolides C-I from the Fijian red alga Callophycus serratus. J Nat Prod 69: 731-735
36. Lane AL, Stout EP, Hay ME, Prusak AC, Hardcastle K, Fairchild CR, Franzblau SG, Le Roch K, Prudhomme J, Aalbersberg W, Kubanek J (2007) Callophycoic acids and callophycols from the Fijian red alga Callophycus serratus. J Org Chem 72: 7343-7351
37. Stout EP, Hassemeyer AP, Lane AL, Davenpot TM, Engel S, Hay ME, Fairchild CR, Prudhomme J, Le Roch K, Aalbersberg W, Kubanek J (2009) Antibacterial Neurymenolides from the Fijian red alga Neurymenia fraxinifolia. Org Lett 11: 225-228
38. Burkepile DE, Hay ME (2008) Herbivore species richness and feeding complementarity affect community structure and function on a coral reef. Proc Natl Acad Sci USA 105: 16201-16206
39. Vagelos PR (1991) Are prescription drug prices high? Science 252: 1080-1084
40. Mullin R (2003) Drug development cost about $1.7 billion. Chem Eng News 81(50): 8-9
41. Angell M (2004) The truth about the drug companies. Random House, New York, 305 p 42.
42. Adams S (1999) SmithKline Beecham: analysis of patenting 1995-1998. Expert Opin Ther Pat 9: 1173-1183